2074 related articles for article (PubMed ID: 16723559)
1. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
2. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
3. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.
Cuenca-Estrella M; Gomez-Lopez A; Mellado E; Buitrago MJ; Monzon A; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2006 Mar; 50(3):917-21. PubMed ID: 16495251
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.
Pfaller MA; Messer SA; Hollis RJ; Jones RN
Antimicrob Agents Chemother; 2001 Oct; 45(10):2862-4. PubMed ID: 11557481
[TBL] [Abstract][Full Text] [Related]
7. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
8. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
[TBL] [Abstract][Full Text] [Related]
9. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA; Messer SA; Hollis RJ; Jones RN;
Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
[TBL] [Abstract][Full Text] [Related]
10. Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B.
Espinel-Ingroff A
J Clin Microbiol; 2006 Oct; 44(10):3616-22. PubMed ID: 16943356
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility testing of Cryptococcus diffluens against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole.
Kantarcioğlu AS; Boekhout T; Yücel A; Altas K
Med Mycol; 2009 Mar; 47(2):169-76. PubMed ID: 18654925
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading.
Uzun O; Arikan S; Kocagöz S; Sancak B; Unal S
Diagn Microbiol Infect Dis; 2000 Oct; 38(2):101-7. PubMed ID: 11035241
[TBL] [Abstract][Full Text] [Related]
13. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
Espinel-Ingroff A
J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
Shi JY; Xu YC; Shi Y; Lü HX; Liu Y; Zhao WS; Chen DM; Xi LY; Zhou X; Wang H; Guo LN
Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates.
Swinne D; Watelle M; Nolard N
Rev Iberoam Micol; 2005 Mar; 22(1):24-8. PubMed ID: 15813679
[TBL] [Abstract][Full Text] [Related]
16. Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections.
Carrillo-Muñoz AJ; Quindós G; Ruesga M; Alonso R; del Valle O; Hernández-Molina JM; McNicholas P; Loebenberg D; Santos P
J Antimicrob Chemother; 2005 Mar; 55(3):317-9. PubMed ID: 15705637
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).
Swinne D; Watelle M; Van der Flaes M; Nolard N
Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180
[TBL] [Abstract][Full Text] [Related]
18. Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study.
Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Fothergill A; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
J Clin Microbiol; 2005 Sep; 43(9):4535-40. PubMed ID: 16145103
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.
Pfaller MA; Messer SA; Rhomberg PR; Jones RN; Castanheira M
J Clin Microbiol; 2013 Aug; 51(8):2608-16. PubMed ID: 23740727
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
Manavathu EK; Cutright JL; Loebenberg D; Chandrasekar PH
J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
